Substituted indazole derivatives
CA 2208792 C · Owner: Pfizer Limited · Inventors: Marfat, Anthony
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are compounds of the formula (see fig.I), wherein the broken line indicates a single or double bond and, preferably R is cyclopentyl or cyclohexyl R1 is ethyl and, either; X1 is ~CR2R3 when the broken line indicates a single bond, wherein R2 is H or hydroxy and R3 is phenyl or pyridin-4-yl, and X2 is -CR5R7R8, wherein R6 is H R7 is pyridin-4-yl, and R8 is H; or X1 is ~CR3 when the broken line indicates a double bond, wherein R3 is phenyl or pyridin-4-yl and X2 is, =CR7R8, wherein R7 is pyridin-4-yl and R8 is H. These compounds are useful for inhibiting phosphodiesterase type IV or the production of tumor necrosis factor in a mammal.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 1997 and granted December 10, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 25, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.